Nicole Burchardi

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

S. Loibl, Michael Untch, Nicole Burchardi et al. · Annals of Oncology · 2019 · 694 citations

Medicine, Oncology, Pharmacology +16

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

Lars Hanker, Sibylle Loibl, Nicole Burchardi et al. · Annals of Oncology · 2012 · 340 citations

Medicine, Gynecology, Oncology +15

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Sibylle Loibl, Frederik Marmé, Miguel Martín et al. · Journal of Clinical Oncology · 2021 · 324 citations

Medicine, Oncology, Pharmacology +17

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Zuzana Kos, Elvire Roblin, Rim S. Kim et al. · npj Breast Cancer · 2020 · 206 citations · Full text

Medicine, Oncology, Pathology +16

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Peter A. Fasching, Theresa Link, Jan Hauke et al. · Annals of Oncology · 2020 · 144 citations · Full text

Medicine, Cancer Biology, Oncology +17